PD-0896 Definitive SBRT in early-stage HCC: an Australian multi-institutional review of outcomes

Liu, Howard; Lee, Y.Y.; Sridharan, Swetha; Wang, W.; Khor, Richard; Chu, Julie; Oar, Andrew; Choong, Ee Siang; Le, Hien; Shanker, Manish; Wigg, Alan; Stuart, Kirsty; Pryor, David

doi:10.1016/s0167-8140(23)09021-7

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The two‐year freedom from local progression was 94%, PFS was 60% and OS was 88% 18 . Grade 2 clinically significant and treatment‐related toxicities were observed in 13.2% patients and there were no grade 3–5 treatment‐related clinical toxicities 18 …”

Section: Discussionmentioning

confidence: 96%

“…In Australia, we have observed an increased utilisation of SBRT in the management of HCC including as a first‐line, curative intent treatment 9 . An Australia multi‐centre retrospective review reported outcomes following curative intent SBRT in 68 patients with treatment naïve BCLC early‐stage, solitary HCC up to 5 cm with compensated CP A cirrhosis 18 . The two‐year freedom from local progression was 94%, PFS was 60% and OS was 88% 18 .…”

Section: Discussionmentioning

confidence: 99%

“…An Australia multi‐centre retrospective review reported outcomes following curative intent SBRT in 68 patients with treatment naïve BCLC early‐stage, solitary HCC up to 5 cm with compensated CP A cirrhosis 18 . The two‐year freedom from local progression was 94%, PFS was 60% and OS was 88% 18 . Grade 2 clinically significant and treatment‐related toxicities were observed in 13.2% patients and there were no grade 3–5 treatment‐related clinical toxicities 18 …”

Section: Discussionmentioning

confidence: 99%

“…18 The two-year freedom from local progression was 94%, PFS was 60% and OS was 88%. 18 Grade 2 clinically significant and treatment-related toxicities were observed in 13.2% patients and there were no grade 3-5 treatment-related clinical toxicities. 18 During the COVID-19 pandemic and in the current health environment with hospital bed pressures, an outpatient treatment modality is invaluable in providing patients with cancer directed treatment within an appropriate time frame.…”

Section: Univariate Analysismentioning

confidence: 94%

See 3 more Smart Citations

Comparison of outcomes following surgical resection, percutaneous ablation or stereotactic body radiation therapy in early‐stage, solitary and small (≤3 cm) treatment‐naïve hepatocellular carcinoma

Maher,

Shanker,

Liu

et al. 2024

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

IntroductionStereotactic body radiation therapy (SBRT) is associated with high local control rates in hepatocellular carcinoma (HCC). This study reports the outcomes of SBRT compared to surgical resection (SR) and percutaneous ablation (PA) for treatment‐naïve, solitary HCCs ≤3 cm.MethodsThis was a retrospective study of patients with BCLC stage 0/A HCC with a single ≤3 cm lesion, treated with curative intent between 2016 and 2020. SBRT was used for patients considered unsuitable for SR or PA. The co‐primary endpoints were progression‐free survival (PFS) and overall survival (OS). The secondary endpoints were treatment‐related clinical toxicity rates and local control (LC) rates.ResultsThere were 112 patients included in this study. SBRT was delivered in 36 patients (32.1%), 51 had PA (45.5%) and 25 underwent SR (22.3%). Median follow‐up was 23 months (range, 3–60 months) from diagnosis. The 3‐year PFS and OS were 67% and 69% following SBRT, 55% and 80% following PA, and 85% and 100% following SR, respectively. Patients in the SR cohort had significantly better 3‐year PFS and OS compared to SBRT and PA groups (p = 0.03 and p = 0.04, respectively). There was no significant difference in PFS (p = 0.15) or OS (p = 0.23) between SBRT and PA treated patients. The 3‐year LC rate for the entire cohort was 98%.ConclusionsIn patients with treatment‐naïve, early‐stage solitary HCCs ≤3 cm, SBRT was associated with comparable PFS, OS and LC outcomes to PA. SBRT should be considered as a curative intent therapy to avoid treatment stage migration in this favourable prognostic cohort of patients.

show abstract

Section: Discussionmentioning

confidence: 96%